Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02756962
Title Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

acute myeloid leukemia

Therapies

Midostaurin

Cytarabine

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST